ReviewSeminars in immunopathology2026
Thymic function as a central determinant of immune competence and clinical outcomes.
Review in Seminars in immunopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The thymus is a central regulator of immune competence, sustaining the continuous generation of a diverse and self-tolerant T-cell repertoire throughout life. Although traditionally regarded as primarily relevant during early development, accumulating evidence highlights its persistent role in shaping adaptive immunity across physiological and pathological conditions. In this review, we examine the role of thymic function as a determinant of immune competence and treatment efficacy across conditions in which adaptive immunity is challenged or therapeutically reshaped, including hematopoietic cell transplantation, severe infections, autoimmune diseases, immune checkpoint inhibitor therapy, and aging. In these contexts, impaired thymic activity is consistently associated with contraction of the naïve T‑cell pool, reduced T‑cell receptor (TCR) diversity, increased susceptibility to immune‑related complications, and inferior clinical outcomes. We then provide a critical overview of the methodologies currently available to assess thymic function, including flow-cytometric identification of recent thymic emigrants, molecular quantification of T‑cell receptor excision circles, analysis of TCR repertoire diversity, and imaging‑based approaches, highlighting their respective strengths, limitations, and translational applicability. Finally, we discuss the emerging relevance of thymic function in the context of adaptive and T‑cell-redirecting therapies, where sustained immune competence depends on the integrity of endogenous T‑cell regeneration. Collectively, this review positions thymic function as a clinically actionable biomarker for immune monitoring, patient stratification, and personalization of adaptive immunotherapies.
Indexed as
Identifiers
42789109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.